Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
J Surg Oncol. 2014 Sep;110(4):451-7. doi: 10.1002/jso.23675. Epub 2014 Jun 25.
This study aimed to establish a correlation between MSI, KRAS mutations, and BRAF(V600E) in colon cancer and to investigate the prognostic effect.
Colon cancer patients who underwent surgical intervention were enrolled. MSI status was identified by genotyping, and the mutational statuses of KRAS and BRAF were determined by MassARRAY, targeting 22 mutations. The clinicopathological differences and correlations between these factors were analyzed.
Among 1,063 patients, tumors with MSI-H were significantly associated with BRAF(V600E) (P = 0.001). KRAS and BRAF mutations were mutually exclusive (P = 0.001). Patients with MSI-H tumors had significantly improved overall survival compared with patients that had microsatellite instability-low/stable (MSI-L/MSS) tumors (hazard ratio 0.686: 95% confidence interval: 0.479-1.162, P = 0.040). In addition, the BRAF(V600E) mutation was a poor prognostic factor in tumors with MSI-L/MSS (P = 0.020). KRAS mutations were not prognostic factors, but sub-group analysis demonstrated that mutations in KRAS codon 12 were associated with significantly worse survival than wild-type KRAS, mutations in KRAS codon 13, or mutations elsewhere.
MSI and the BRAF(V600E) mutation have a prognostic impact in colon cancer. Variable KRAS mutations may have different effects on colon cancers; further studies are needed to verify these results.
本研究旨在建立结直肠癌中 MSI、KRAS 突变和 BRAF(V600E)之间的相关性,并探讨其预后影响。
纳入接受手术干预的结直肠癌患者。通过基因分型确定 MSI 状态,通过 MassARRAY 针对 22 个突变检测 KRAS 和 BRAF 的突变状态。分析这些因素的临床病理差异和相关性。
在 1063 例患者中,MSI-H 肿瘤与 BRAF(V600E)显著相关(P=0.001)。KRAS 和 BRAF 突变是相互排斥的(P=0.001)。与微卫星不稳定低/稳定(MSI-L/MSS)肿瘤相比,MSI-H 肿瘤患者的总生存期明显延长(风险比 0.686:95%置信区间:0.479-1.162,P=0.040)。此外,BRAF(V600E)突变是 MSI-L/MSS 肿瘤的不良预后因素(P=0.020)。KRAS 突变不是预后因素,但亚组分析表明,KRAS 密码子 12 的突变与野生型 KRAS、KRAS 密码子 13 的突变或其他部位的突变相比,与生存率显著降低相关。
MSI 和 BRAF(V600E)突变对结直肠癌有预后影响。KRAS 突变的可变可能对结直肠癌有不同的影响,需要进一步的研究来验证这些结果。